<DOC>
	<DOCNO>NCT02433158</DOCNO>
	<brief_summary>This open label extension study subject Sickle Cell Disease ( SCD ) complete double blind Phase 3 study ( B5201002 ) .</brief_summary>
	<brief_title>Safety Of Rivipansel ( GMI-1070 ) In The Treatment Of One More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease</brief_title>
	<detailed_description>This open label extension study subject 6 year age old Sickle Cell Disease ( SCD ) complete double blind Phase 3 study ( B5201002 ) . This study design evaluate safety describe efficacy rivipansel treatment one vaso-occlusive crisis ( VOC ) event hospitalize subject SCD .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Completion Study B5201002 . Documented diagnosis SCD . At least 6 year age . Male female subject childbearing potential risk pregnancy must agree use highly effective method contraception throughout study . Diagnosis VOC necessitate IV opioids admission hospital . Able receive first dose rivipansel within 24 hour administration first dose IV opioids hospitalization . Non compliance study procedure double blind study ( B5201002 ) . Occurrence severe and/or generalize cutaneous manifestation adverse event participation Study B5201002 relate study drug would therefore make inappropriate subject receive rivipansel current study . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration may interfere interpretation study result . Clinically significant deterioration renal function Study B5201002 . Pregnant female subject , breastfeed female subject male female subject childbearing potential unwilling unable use highly effective method contraception . Active use illicit drug and/or alcohol dependence .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Rivipansel</keyword>
	<keyword>GMI-1070</keyword>
	<keyword>Selectin Inhibitor</keyword>
	<keyword>SCD</keyword>
	<keyword>VOC</keyword>
</DOC>